Skip to main content
. 2019 Jan 28;5(2):277–289. doi: 10.1021/acscentsci.8b00688

Figure 7.

Figure 7

Treatment with F-DMA/CCL19 programmed macrophage phenotype to M1. When CT26 cells were transfected with GS, F-DMA, F-DMA/pVax, DMA/CCL19, and F-DMA/CCL19 for 72 h, the supernatants from different treatments were added to peritoneal derived macrophage cells and treated for 24 h. The cells were stained with CD45, CD11b, F4/80, and CD206 antibodies. The percentage of CD11b+F4/80+CD206high M2 macrophage cells is shown (mean ± SEM, n = 3; *, p < 0.05, **, p < 0.01; F-DMA/CCL19 versus DMA/CCL19; F-DMA/CCL19, DMA/CCL19 versus GS, DMA, DMA/pVax). The results represent three independent experiments.